AGIO — Agios Pharm

Agios Pharm (AGIO) is a biotechnology company listed on NASDAQ. It is led by Brian M. Goff M.B.A., based in 88 Sidney Street, Cambridge, MA, United States, 02139, with about 539 employees. Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Latest reported AGIO revenue for 2025-09-30 was $12.9M. Net income was -$103.4M. Revenue was up 3.4% from 2025-06-30 to 2025-09-30. AGIO currently screens at market cap $1.68B.

Use this AGIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AGIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AGIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Agios Pharm even when a live quote feed is slow.